Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: A clinical pharmacokinetic study

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue 2, 2018, Pages 477-483

  Heinrichs, M Tobias ^a   Vashakidze, Sergo ^b   Nikolaishvili, Ketino ^b   Sabulua, Irina ^b   Tukvadze, Nestani ^b   Bablishvili, Nino ^b   Gogishvili, Shota ^b   Little, Brent P ^c   Bernheim, Adam ^c   Guarner, Jeannette ^c   Peloquin, Charles A ^a   Blumberg, Henry M ^c,d   Derendorf, Hartmut ^a   Kempker, Russell R ^c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b National Center for Tuberculosis and Lung Diseases   (Georgia)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GYRASE INHIBITOR; MOXIFLOXACIN; TUBERCULOSTATIC AGENT;

ADULT; CHEMISTRY; FEMALE; GEORGIA (REPUBLIC); HUMAN; LUNG; LUNG TUBERCULOSIS; MALE; MICRODIALYSIS; MIDDLE AGED; MULTIDRUG RESISTANT TUBERCULOSIS; SERUM; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; FEMALE; GEORGIA (REPUBLIC); HUMANS; LUNG; MALE; MICRODIALYSIS; MIDDLE AGED; MOXIFLOXACIN; SERUM; TOPOISOMERASE II INHIBITORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 85057237690     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx421     Document Type: Article

References (32)

1. WHO. Global Tuberculosis Report 2016 (WHO/HTM/TB/2016.13). Geneva, Switzerland: WHO, 2016. http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1.
2. WHO. A Global Action Framework for TB Research: In Support of the Third Pillar ofWHO's End TB Strategy (WHO/HTM/TB/2015.26). Geneva, Switzerland: WHO, 2015. http://apps.who.int/iris/bitstream/10665/195772/1/97892415 09756-eng.pdf?ua=1.
3. Lienhardt C, Lönnroth K, Menzies D et al. Translational research for tuberculosis elimination: priorities, challenges, and actions. PLoS Med 2016; 13: e1001965.
4. Prideaux B, Via LE, Zimmerman MD et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med 2015; 21: 1223-7.
5. Bastos ML, Hussain H, Weyer K et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 2014; 59: 1364-74.
6. Pletz MWR, De Roux A, Roth A et al. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004; 48: 780-2.
7. Lakshminarayana SB, Huat TB, Ho PC et al. Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. J Antimicrob Chemother 2015; 70: 857-67.
8. Vaddady PK, Lee RE, Meibohm B. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. Future Med Chem2010; 2: 1355-69.
9. Drusano G. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300.
10. Scaglione F. Pharmacokinetic/pharmacodynamic (PK/PD) considerations in the management of Gram-positive bacteraemia. Int J Antimicrob Agents 2010; 36 Suppl 2: S33-9.
11. Kempker RR, Kipiani M, Mirtskhulava V et al. Acquired drug resistance in Mycobacterium tuberculosis and poor outcomes among patients with multidrug-resistant tuberculosis. Emerg Infect Dis 2015; 21: 992-1001.
12. Deitchman AN, Heinrichs MT, Khaowroongrueng V et al. Utility of microdialysis in infectious disease drug development and dose optimization. AAPS J 2017; 19: 334-42.
13. Azeredo FJ, Dalla Costa T, DerendorfH. Role ofmicrodialysis in pharmacokinetics and pharmacodynamics: current status and future directions. Clin Pharmacokinet 2014; 53: 205-12.
14. Kempker RR, HeinrichsMT, Nikolaishvili K et al. Lung tissue concentrations of pyrazinamide among patientswith drug-resistant pulmonary tuberculosis. Antimicrob Agents Chemother 2017; 61: e00226-17.
15. Kempker RR, Barth AB, Vashakidze S et al. Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2015; 59: 3149-55.
16. Stass H, Dalhoff A, Kubitza D et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42: 2060-5.
17. Ostergaard C, Sørensen TK, Knudsen JD et al. Evaluation ofmoxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob Agents Chemother 1998; 42: 1706-12.
18. Müller M, Stass H, Brunner M et al. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999; 43: 2345-9.
19. US FDA. NDA 21-085 Avelox Clinical Pharmacology and Biopharmaceutics Review. 1998. https://www.accessdata.fda.gov/drugsatfda-docs/nda/99/21-085-Avelox-biopharmr.pdf.
20. LaMorte WW. Mann Whitney U Test (Wilcoxon Rank Sum Test). http://sphweb.bumc.bu.edu/otlt/mph-modules/bs/bs704-nonparametric/BS704- Nonparametric4.html.
21. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74: 839-54.
22. Lubasch A, Keller I, Borner K et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44: 2600-3.
23. Peloquin CA, Hadad DJ, Molino LP et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 852-7.
24. NimmoWS, Peacock JE. Effect of anaesthesia and surgery on pharmacokinetics and pharmacodynamics. Br Med Bull 1988; 44: 286-301.
25. Wood M. Pharmacokinetic drug interactions in anaesthetic practice. Clin Pharmacokinet 1991; 21: 285-307.
26. Michot JM, Seral C, Van Bambeke F et al. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob Agents Chemother 2005; 49: 2429-37.
27. Hutschala D, Skhirtladze K, Kinstner C et al. In vivo microdialysis tomeasure antibiotic penetration into soft tissue during cardiac surgery. Ann Thorac Surg 2007; 84: 1605-10.
28. de Lange ECM, Recovery and calibration techniques: toward quantitative microdialysis. In: Mueller M, ed. Microdialysis in Drug Development. NewYork, NY, USA: Springer, 2013; 13-33.
29. Grosset J. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother 2003; 47: 833-6.
30. Breilh D, Jougon J, Djabarouti S et al. Diffusion of oral and intravenous 400mg once-dailymoxifloxacin into lung tissue at pharmacokinetic steadystate. JChemother 2003; 15: 558-62.
31. Gumbo T, Louie A, Deziel MR et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-51.
32. National Kidney Foundation. Cockcroft-Gault Formula. https://www.kid ney.org/professionals/KDOQI/gfr-calculatorCoc.